CA2322748A1 - Facteur de croissance endothelial vasculaire 2 - Google Patents

Facteur de croissance endothelial vasculaire 2 Download PDF

Info

Publication number
CA2322748A1
CA2322748A1 CA002322748A CA2322748A CA2322748A1 CA 2322748 A1 CA2322748 A1 CA 2322748A1 CA 002322748 A CA002322748 A CA 002322748A CA 2322748 A CA2322748 A CA 2322748A CA 2322748 A1 CA2322748 A1 CA 2322748A1
Authority
CA
Canada
Prior art keywords
polypeptide
vegf
polypeptides
sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002322748A
Other languages
English (en)
Inventor
Craig A. Rosen
Liang Cao
Jing-Shan Hu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/042,105 external-priority patent/US6040157A/en
Priority claimed from US09/107,997 external-priority patent/US7186688B1/en
Application filed by Individual filed Critical Individual
Publication of CA2322748A1 publication Critical patent/CA2322748A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des polypeptides humains du facteur de croissance endothélial vasculaire 2, des fragments, analogues ou dérivés de ces polypeptides, actifs sur le plan biologique et utiles sur les plans diagnostique et thérapeutique, ainsi que l'ADN (ARN) codant ces polypeptides. L'invention concerne également des procédés de production de tels polypeptides à l'aide de techniques de recombinaison, de même que des anticorps et antagonistes dirigés contre de tels polypeptides. On peut utiliser ces polypeptides et polynucléotides de manière thérapeutique pour stimuler la cicatrisation de plaies et dans la réparation de tissus vasculaires. L'invention concerne encore des procédés d'utilisation de ces anticorps et antagonistes, destinés à inhiber l'angiogenèse de tumeurs et donc la croissance de celles-ci, l'inflammation, la rétinopathie diabétique, la polyarthrite rhumatoïde et le psoriasis.
CA002322748A 1998-03-13 1999-03-10 Facteur de croissance endothelial vasculaire 2 Abandoned CA2322748A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/042,105 US6040157A (en) 1994-03-08 1998-03-13 Vascular endothelial growth factor 2
US09/042,105 1998-03-13
US09/107,997 1998-06-30
US09/107,997 US7186688B1 (en) 1994-03-08 1998-06-30 Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
PCT/US1999/005021 WO1999046364A1 (fr) 1998-03-13 1999-03-10 Facteur de croissance endothelial vasculaire 2

Publications (1)

Publication Number Publication Date
CA2322748A1 true CA2322748A1 (fr) 1999-09-16

Family

ID=26718873

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002322748A Abandoned CA2322748A1 (fr) 1998-03-13 1999-03-10 Facteur de croissance endothelial vasculaire 2

Country Status (7)

Country Link
EP (1) EP1062319A4 (fr)
JP (1) JP2002505873A (fr)
KR (1) KR20010034576A (fr)
CN (1) CN1299407A (fr)
AU (1) AU3072099A (fr)
CA (1) CA2322748A1 (fr)
WO (1) WO1999046364A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US5932540A (en) 1994-03-08 1999-08-03 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6734285B2 (en) 1994-03-08 2004-05-11 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 proteins and compositions
ES2249762T3 (es) 1994-03-08 2006-04-01 Human Genome Sciences, Inc. Factor de crecimiento del endotelio vascular 2.
US7186688B1 (en) 1994-03-08 2007-03-06 Human Genome Sciences, Inc. Methods of stimulating angiogenesis in a patient by administering vascular endothelial growth factor 2
US6040157A (en) 1994-03-08 2000-03-21 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US7109308B1 (en) 1994-03-08 2006-09-19 Human Genome Sciences, Inc. Antibodies to human vascular endothelial growth factor 2
US7153827B1 (en) 1994-03-08 2006-12-26 Human Genome Sciences, Inc. Vascular endothelial growth factor 2 and methods of use
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
PT848755E (pt) 1995-09-08 2003-12-31 Genentech Inc Proteina relacionada com o vegf
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
AU6691098A (en) * 1997-03-07 1998-09-22 Wistar Institute Of Anatomy & Biology, The Method and compositions for healing tissue defects and inducing hypervascularityin mammalian tissue
US6958147B1 (en) 1998-10-26 2005-10-25 Licentia Ltd Use of VEGF-C to prevent restenosis
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
US6764820B2 (en) 1999-03-26 2004-07-20 Ludwig Institute For Cancer Research Screening for lymphatic disorders involving the FLT4 receptor tyrosine kinase (VEGFR-3)
WO2000058511A1 (fr) 1999-03-26 2000-10-05 Ludwig Institute For Cancer Research Dosage et therapie pour les troubles lymphatiques impliquant la tyrosine kinase flt4 (vegfr-3)
ATE526981T1 (de) 2000-04-12 2011-10-15 Vib Vzw Verwendung von vegf 165 und homologen zur behandlung von neurologischen störungen
US7273751B2 (en) 2000-08-04 2007-09-25 Human Genome Science, Inc. Vascular endothelial growth factor-2
US7026462B2 (en) 2000-12-07 2006-04-11 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
EP2228389B1 (fr) * 2001-04-13 2015-07-08 Human Genome Sciences, Inc. Anticorps contre facteur de croissance endothéliale vasculaire 2
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US7217570B2 (en) 2001-08-23 2007-05-15 The Wistar Institute Of Anatomy And Biology Organotypic intestinal culture and methods of use thereof
EP1532268A4 (fr) * 2002-03-21 2006-07-05 Yissum Res Dev Co Marqueurs de cellules sanguines peripheriques utiles pour le diagnostic de la sclerose en plaques et procedes et trousses comprenant de tels marqueurs
AU2003304173A1 (en) 2002-05-04 2005-01-04 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
MXPA05012307A (es) * 2003-05-16 2006-07-03 Acorda Therapeutics Inc Mutantes que degradan proteoglicanos para tratamiento del snc.
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
JP4926962B2 (ja) 2004-05-18 2012-05-09 アコーダ セラピューティクス、インク． コンドロイチン分解酵素とその安定な製剤の精製法
DE602005023155D1 (de) 2004-05-27 2010-10-07 Life Sciences Res Partners Vzw Behandlung von amyotrohper lateralsklerose
US7358085B2 (en) 2005-02-28 2008-04-15 Sangamo Biosciences, Inc. Anti-angiogenic methods and compositions
CA2623635C (fr) 2005-09-26 2013-04-02 Acorda Therapeutics, Inc. Compositions et procedes d'utilisation de mutants des chondroitinases abci
CN100448892C (zh) * 2006-08-02 2009-01-07 中国人民解放军军事医学科学院基础医学研究所 抗肿瘤血管内皮生长因子受体vegf－r2抗原及其编码基因与应用
ES2473610T3 (es) 2006-10-10 2014-07-07 Acorda Therapeutics, Inc. Composiciones y métodos de uso de mutantes de condroitinasa ABCI

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2249762T3 (es) * 1994-03-08 2006-04-01 Human Genome Sciences, Inc. Factor de crecimiento del endotelio vascular 2.
US6608182B1 (en) * 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
WO1998033917A1 (fr) * 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Proteine et gene du facteur de croissance vasculaire endothelial c (vegf-c), mutants de ce dernier et utilisations
US6645933B1 (en) * 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
PT848755E (pt) * 1995-09-08 2003-12-31 Genentech Inc Proteina relacionada com o vegf
AU1116297A (en) * 1995-11-08 1997-05-29 Immunex Corporation Flk-1 binding protein
ES2212121T3 (es) * 1996-08-13 2004-07-16 Human Genome Sciences, Inc. Mutantes de factor-2 de crecimiento queranocitico (kgf-2 o factor -12 de crecimiento fibroblastico, fgf-12).
JP2001524828A (ja) * 1997-04-25 2001-12-04 コラテラル・セラピューティクス 切断型ｖｅｇｆ関連蛋白質

Also Published As

Publication number Publication date
JP2002505873A (ja) 2002-02-26
AU3072099A (en) 1999-09-27
EP1062319A4 (fr) 2003-04-23
KR20010034576A (ko) 2001-04-25
EP1062319A1 (fr) 2000-12-27
WO1999046364A9 (fr) 1999-11-18
WO1999046364A1 (fr) 1999-09-16
CN1299407A (zh) 2001-06-13

Similar Documents

Publication Publication Date Title
US7153942B2 (en) Vascular endothelial growth factor 2
US6734285B2 (en) Vascular endothelial growth factor 2 proteins and compositions
US20060057117A1 (en) Vascular endothelial growth factor 2
CA2322748A1 (fr) Facteur de croissance endothelial vasculaire 2
US9403905B2 (en) Vascular endothelial growth factor 2
US20060025331A1 (en) Vascular endothelial growth factor 2
US20050059117A1 (en) Vascular endothelial growth factor 2
AU2002257142A1 (en) Vascular endothelial growth factor 2
WO2002083850A2 (fr) Facteur 2 de croissance endotheliale vasculaire
WO2003097660A1 (fr) Facteur de croissance endothelial vasculaire 2
AU2003264585A1 (en) Vascular Endothelial Growth Factor 2
MXPA00008920A (en) Vascular endothelial growth factor 2

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead